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Purpose: Although post-void residual urine (PVR) is frequently utilized clinically in patients with benign prostatic hyperplasia 
(BPH), mainly because of its procedural simplicity, its role as a clinical prognostic factor, predictive of treatment goals, is still un-
der much dispute. We investigated the predictive value of PVR for BPH-related clinical events including surgery, acute urinary 
retention (AUR), and admission following urinary tract infection (UTI).
Methods: From January to June of 2006, patients over 50 years of age who were diagnosed with BPH for the first time at the out-
patient clinic and were then treated for at least 3 years with medications were enrolled in this study. The variables of patients who 
underwent surgical intervention for BPH, had occurrences of AUR, or required admission due to UTI (Group 1, n=43) were 
compared with those of patients who were maintained with medications only (Group 2, n=266).
Results: Group 1 had a significantly higher PVR, more severe symptoms, and a larger prostate at the time of the initial diagnosis 
in both the univariate and the multivariate analysis. In the 39 patients who underwent BPH-related surgery, although there was 
a significant change in Qmax at the time of surgery (mean, 13.1 months), PVR and the symptom score remained unchanged 
compared with the initial evaluation. In the receiver-operating characteristic curve analysis, the area under the curve of Group 1 
was in the order of prostate volume (0.834), PVR (0.712), and symptom score (0.621). When redivided by arbitrarily selected 
PVR cutoffs of 50 mL, 100 mL, and 150 mL, the relative risk of clinical BPH progression was measured as 3.93, 2.61, and 2.11.
Conclusions: These data indicate that, in the symptomatic Korean population, increased PVR at baseline is a significant indica-
tor of BPH-related clinical events along with increased symptom score or prostate volume. 
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INTRODUCTION
Benign prostatic hyperplasia (BPH) is a progressive disease that 
is characterized mainly by a deterioration of symptoms over time 
[1] but also by the occurrence in some patients of serious out-
comes, such as acute urinary retention (AUR), urinary tract in-
fection (UTI), and the need for BPH-related surgery [2]. Goals 
of therapy are not only to improve symptoms and restore an ac-
ceptable quality of life but also to identify patients at risk of dis-
ease progression in order to optimize their management.
  Although urodynamic studies are the most sensitive tools for 
determination of the presence and grade of bladder outlet ob-
struction (BOO), these studies require invasive and uncomfort-
able procedures as well as the use of expensive equipment. In a 
clinical setting, measurement of the volume of residual urine in 
the bladder after voiding is a common procedure in the urolog-
ical examination of patients presenting with lower urinary tract 
symptoms (LUTS) and has traditionally been thought to have a 
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prominent role in identifying those with an obstruction [1]. 
However, there is no agreement at present as to the usefulness 
of postvoid residual urine (PVR) as a clinical prognostic factor 
or in the prediction of treatment goals. Recent data from West-
ern, longitudinal, population-based studies and placebo-con-
trolled studies have suggested PVR as an important predictor 
for BPH-related surgery and the development of AUR [3-5]. 
However, considering that race and geographic factors influence 
the growth of the normal human prostate and the risk of symp-
tomatic BPH [6], the clinical manifestation of PVR in BPH pa-
tients may also be affected by ethnicity. To the best of our knowl-
edge, intensive epidemiological research on this issue among 
members of an Asian population, who generally have smaller 
prostates than do members of Western populations [7,8], has 
not yet been reported. Hence, the generalization of results from 
Western to Asian populations is uncertain. Therefore, in order 
to obtain a better understanding of this issue, we investigated 
the clinical implications of PVR in the Korean population by 
evaluating its relationship with other variables and its predictive 
value for BPH-related clinical events, including surgery, AUR, 
and admission following UTI. 
MATERIALS AND METHODS
Patient Selection and Data Collection
From January to June of 2006, men over 50 years of age who had 
visited the outpatient clinic of a single institute for the first time 
with a chief complaint of LUTS, who were diagnosed as having 
BPH after routine initial evaluation, and who were then followed 
up for at least 3 years with medication were enrolled in this study. 
Routine evaluation for LUTS patients in our institute includes 
uroflowmetry with measurement of PVR, completion of the 
International Prostate Symptom Score (IPSS) questionnaire, 
measurement of prostate volume by transrectal ultrasonography 
(TRUS) after digital rectal examination, urinalysis, and measure-
ment of serum prostate-specific antigen and creatinine. 
  Uroflowmetry was performed with the patient in the standing 
position, and the voided volume and maximal flow rate (Qmax) 
were recorded continuously during micturition. Only flows for 
which the sum of the voided volumes and PVR was at least 150 
mL without possible artifacts were included. If the sum was be-
low 150 mL at the initial evaluation, uroflowmetry was rechecked 
at the next visit. With the patient in a supine position, PVR was 
measured immediately after uroflowmetry by ultrasonography 
with a 7.5 MHz linear probe. With the probe parallel two fin-
gers above the symphysis pubis of the patient, an image of the 
largest circumference of the bladder was captured on the screen. 
PVR was calculated by application of the following formula: 
sagittal height X sagittal depth X transverse width X 0.625 [9]. 
After approval from the local institutional review board, these 
variables were surveyed from a retrospective review of medical 
records, and 309 patients with IPSS over 7 and Qmax below 15 
mL/sec were finally selected. We included the patients who are 
enough to be diagnosed as BPH by clinical symptoms and the 
evaluation test though the prostate volume of the selected pa-
tients are smaller than 20-30 g which is considered as normal 
volume in general. Patients with hematuria or pyuria, prostate-
specific antigen (PSA) over 4 ng/dL at the initial screening, or 
prior prostate surgery or medication for LUTS were excluded 
in this series. In addition, this study excluded non-genitourinary 
conditions that affect volume of PVR such as diabetes mellitus 
or neurological disease. 
  By analysis of their medical records, the patients were divid-
ed into two groups: patients who underwent surgical interven-
tions for BPH, including transurethral resection of the prostate 
(TURP) or laser-based transurethral prostate surgery; experi-
enced the occurrence of AUR; or required admission due to UTI 
during follow-up (Group 1) and counterpart patients who were 
maintained with medications only without occurrence of these 
events (Group 2). Parameters of both groups were compared 
and analyzed. For patients who underwent BPH-related sur-
gery, uroflowmetry and IPSS were routinely rechecked at the 
time of surgery, and the change from the baseline evaluation was 
also analyzed. 
Statistical Analysis
Statistical analysis was carried out by using a commercially avail-
able data analysis program, the SPSS ver. 12.0 (SPSS Inc., Chi-
cago, IL, USA). Correlations between baseline PVR and other 
clinical parameters were determined by using the Pearson cor-
relation test. Descriptive statistics are presented as mean± 
standard error or numbers, according to the variables. Clinical 
characteristics were individually entered into the univariate 
model and were entered into the multivariate logistic regression 
analyses as dependent variables. Odds ratios and P-values for 
trends by univariate and multivariate analysis were estimated 
for determination of factors that predicted BPH-related clinical 
events. If a variable showed statistical significance in the multi-
variable analysis, we used receiver operating characteristic 
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discriminative or diagnostic value of each variable, and the area 
under the ROC curve was measured. All statistical tests were 
two-sided, with a significant threshold set at P<0.05.
RESULTS 
The mean age of the enrolled patients was 67.5±7.8 years; their 
mean PVR was 49.1±63.1 mL, their Qmax was 9.1±4.2 mL/
sec, their IPSS score was 18.2±7.2, their prostate volume was 
29.5±18.2 g, and their PSA level was 1.3±0.9 ng/dL. At the 
baseline evaluation, the amount of PVR was statistically related 
in a positive fashion with IPSS score (Pearson correlation coef-
ficient, +0.20; P<0.001), prostate volume (+0.16, P=0.005), and 
serum PSA level (+0.13, P=0.022) and was statistically related 
in a negative fashion to Qmax (-0.23, P<0.001).
  During a mean follow-up of 39.8±7.2 months, 43 patients 
were designated as Group 1, of whom 39 patients had under-
gone BPH-related surgery, 2 patients experienced AUR, and 1 
patient experienced acute prostatitis. Among the 39 patients 
who required BPH-related surgeries, TURP was conducted in 
21 patients, and laser-based surgery was performed in 18 pa-
tients. The mean duration from initial visit to surgery was 
13.1±18.7 months for BPH-related surgery patients, 30±20.4 
months for AUR patients, and 25 months for the prostatitis pa-
tient. 
  The characteristics of each group are summarized in Table 1. 
When we divided the patients into the two groups, Group 1 was 
significantly older and had a higher PVR, decreased Qmax, more 
severe symptoms, larger prostate, and higher serum PSA at the 
time of initial diagnosis. Multivariate analysis reconfirmed the 
significant differences in terms of PVR, IPSS, and prostate vol-
ume; however, the odds ratio of each variable was low (1.005, 
1.07, and 1.05, respectively). In the 39 patients who underwent 
BPH-related surgery, although the change in Qmax at the time 
of surgery was significant (from 8.3±3.3 to 10.3±3.4 mL/sec), 
IPSS and PVR remained unchanged compared with the initial 
evaluation (Table 2). 
  For the ROC curve, the area under the curve was in the order 
of prostate volume (0.834), PVR (0.712), and symptom score 
(0.621) (Fig. 1). Using PVR, the cutoff point identifying Group 
Table 1.  Characteristics of the patients in each group
Parameter  Total patient 
Group 1 
(n = 43, 13.9%) 
Group 2 
(n = 266, 86.1%) 
Univariate Multivariate
P-value P-value  Odds ratio
Age (yr)  67.5±7.8  70.7±6.0 66.9±7.9 <0.01 0.21 1.03
VV (mL)  206±123 194±123 207±124 0.51 0.83 1.0
PVR (mL) 49.1±63.1 76.7±70.6 41.1±60.5 <0.01  0.04 1.005
PVR/VV  0.3±0.8  0.6±0.7 0.4±1.3 0.19  0.44 0.78
Qmax (mL/sec) 9.1±4.2 8.1±3.1 9.3±4.4 0.03 0.61 0.97
IPSS 18.2±7.2 20.9±7.6 17.8±7.1 0.015  0.03 1.07
QOL 3.9±1.2 4.2±1.0 3.9±1.2 0.053  0.45 1.15
Prostate volume (g) 29.5±18.2 44.9±17.4 27.0±17.1 <0.01  <0.001 1.05
PSA (ng/dL) 1.3±0.9 1.7±0.9 1.3±0.9 <0.01 0.73 1.08
Creatinine (ng/mL)  1.1±0.2 1.7±0.2 1.1±0.2 0.85 0.83 1.27
Values are presented as mean±standard error.
VV, voiding volume; PVR, post-void residual urine; Qmax, maximal flow rate; IPSS, International Prostate Symptom Score; QOL, quality of life; 
PSA, prostate-specific antigen.
Table 2.  Changes in variables in the BPH-related surgery group
Parameter 
At baseline 
evaluation (n=39) 
At time of 
operation (n=39) 
P-value
VV (mL)  200.6±131 219.7±97 0.50
PVR (mL) 69.0±57.5 61.2±51.7 0.56 
PVR/VV  0.51±0.6 0.33±0.3 0.11 
Qmax (mL/sec) 8.3±3.3 10.3±3.4 0.016
IPSS 21.3±7.7 20.5±10.4 0.83 
QOL 4.4±0.9 4.1±1.1 0.37 
Values are presented as mean±standard error.
BPH, benign prostatic hyperplasia; VV, voiding volume; PVR, post-
void residual urine; Qmax, maximal flow rate; IPSS, International 
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1 with 90% specificity was 122 mL, but the sensitivity at this 
point was only 21%. The 72% sensitivity cutoff using PVR was 
28.5 mL, but the specificity at this point was limited as 67.3%. 
Due to these limitations in identification of an acceptable cutoff 
with sufficient sensitivity and specificity at the same time, the 
whole patient group was redivided by arbitrarily selected cutoffs 
of 50 mL, 100 mL, and 150 mL. In this analysis, 51.2% (22/43) 
of Group 1 had PVR over 50 mL, 25.6% (11/43) had PVR over 
100 mL, and 13.9% (6/43) had PVR over 150 mL (P<0.001, 
0.027, and 0.13, respectively, by chi-square test) (Table 3). The 
relative risk of a BPH-related clinical event using each PVR cut-
off was measured as 3.93 (95% confidence interval [CI], 2.02 to 
7.65), 2.61 (95% CI, 1.19 to 5.569), and 2.11 (95% CI, 0.79 to 
5.62), respectively. However, the majority of patients at each 
PVR cutoff were in Group 2: 71.8% (56/78) with PVR over 50 
mL, 73.8% (31/42) with PVR over 100 mL, and 76% (19/25) 
with PVR over 150 mL. 
DISCUSSION
The evaluation of patients with BPH requires a thorough un-
derstanding of the physiology of voiding and of the potential 
pathophysiologic changes. Despite the controversy over the use 
of PVR in BPH patients as a diagnostic and prognostic test, PVR 
continues to be used mainly because of its procedural simplici-
ty, and has been thought to have a prominent role in identifying 
those with obstructions. However, the pathophysiology of PVR 
is not generally well understood, and interactions with BOO 
and detrusor contractility are complex. Although a lack of PVR 
clearly indicates that the patient can efficiently empty his blad-
der, it does not exclude the presence of BOO [10]. In the case of 
increased PVR, although it may result from BOO [11], differ-
entiation of other causes, including deficient bladder contractil-
ity, as the primary cause of symptoms is impossible without a 
pressure-flow study. Moreover, a large PVR may reflect detru-
sor underactivity rather than BOO [12]. 
  The aim of the present study was to evaluate the clinical im-
plications of PVR as a prognostic factor for BPH progression. 
First, we measured baseline variables for all enrolled patients 
who visited our institution for LUTS and investigated the cor-
relation of PVR with other variables. The data showed that PVR 
was correlated with Qmax, IPSS, prostate volume, and serum 
PSA. Similar to our results, PVR has been reported to have a 
statistically significant association with prostate volume [3], se-
verity of symptoms, maximal flow rate [13], and age [14]. Kol-
man et al. [3] investigated PVR and prostate volume in 477 ran-
domly selected community-dwelling white men and reported a 
significant correlation of PVR and prostate volume (P<0.001). 
The odds of PVR greater than 50 mL was 2.5 times greater for 
men with a prostate volume of 30 mL than for those with small-
Table 3.  Division of each patient group dependent on each arbitrarily selected PVR cutoffs
PVR (mL) cutoff
≥50 <50  ≥100 <100 ≥150    <150
Group 1 (n=43) 22 (51.2)  21 (48.8) 11 (25.6)  32 (74.4) 6 (13.9)  37 (86.1)
Group 2 (n=266)   56 (21.0)  210 (79.0) 31 (11.6)  235 (88.4) 19 (7.1)   247 (92.9)
Values are presented as number (%).
PVR, post-void residual urine.
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Fig. 1. Receiver-operating characteristic curve analysis of post 
voiding residual volume (PVR), International Prostate Symp-
tom Score (IPSS), and prostate volume in patients with or with-
out prostate surgery, acute urinary retention, urinary tract infec-
tion.
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er prostates. In an analysis of 198 patients after treatment of BPH, 
Barry et al. [13]. demonstrated that reduction of the symptoms 
score was significantly correlated with improvement of uro-
flowmetry, including PVR. However, others have found no cor-
relation between PVR and LUTS [15] and prostate volume [16]. 
Also, despite a correlation with prostate volume, Kolman et al. 
[3] found no significant relationship between PVR and Qmax, 
age, or symptom score. In our report, the relationships of PVR 
with other variables were very weak, with a coefficient of corre-
lation ranging from 0.1 to 0.3. These weak correlations are con-
sistent with the findings of Kranse and van Mastrigt [17], who 
analyzed the relationship of PVR and the International Conti-
nence Society nomogram for the definition of BOO. In their 
report, areas under the ROC curve were estimated as 0.63 and 
0.64, respectively. 
  The poor baseline correlations shown in the above series in-
dicate the unreliability of PVR as a single dependent parameter 
indicating BOO. Actually, correct interpretation of PVR mea-
surement takes into consideration at least 2 aspects: the great 
variability in the male population and the significant number of 
asymptomatic patients with increased residual volume [18]. 
Physiologic measures always exhibit some degree of intra-indi-
vidual variation, and Birch et al. [19] reported that of 30 men, 
66% had significant variations in PVR when three scans were 
performed on the same day. In an attempt to decrease intra-in-
dividual variation, Memon and Ather [20] suggested the con-
cept of residual fraction, reporting a more accurate and repro-
ducible index of bladder emptying. The efficacy of this novel 
concept in the identification of BOO patients has been support-
ed by other authors [21]. However, in this series, it showed no 
predictability in the identification of patients with clinical BPH 
progression. Considering these limitations, Kou [22] suggested 
the concept of the prostate score, which provided better sensitiv-
ity for patients with BOO, based on a combination of variables 
from uroflowmetry, including PVR and prostate volume mea-
surement by TRUS. 
  In this study with a minimum 3-year follow up, we evaluated 
PVR as an indicator of BPH-related clinical events in members 
of the Korean population. Although most patients (86.1%) were 
maintained with medication, patients with BPH-related clinical 
events had a significantly larger prostate volume, aggravated 
symptoms, and increased PVR at time of initial evaluation. In 
patients with a baseline PVR over 50 mL, the relative risk of 
BPH-related clinical events was 3.9 times greater than for those 
with a smaller PVR, and it was 2.6 times with a baseline PVR 
over 100 mL. Particularly for PVR, these observations had al-
ready been previously reported in Western community-based 
longitudinal studies and placebo-controlled studies. In an Olm-
sted County study, which included 477 randomly selected men, 
men with a baseline PVR of <50 mL were also three times as 
likely to develop subsequent AUR requiring catheterization dur-
ing follow-up [3]. In the Medical Therapy of Prostatic Symptoms 
study, which included 3,047 men with moderate to severe LUTS, 
higher baseline PVR was associated with a slightly greater risk 
of developing BPH-related clinical progression [23]. In a recent 
Western longitudinal population-based study with a follow-up 
period of 6.5 years for 1,688 men, multivariate analysis showed 
that PVR was one of the independent determinants with a sig-
nificant hazard radio in prediction of an increase of IPSS great-
er than 7 [5]. In this study, however, the relative risk of a BPH-
related clinical event is high with more than the each PVR cut-
off, but the dose-response relation is not shown. The reason 
seems to be that as PVR cutoff gets bigger the number of sub-
ject patients that have more than the cutoff gets smaller. This is 
a problem due to the fact that the number of patients of Group 
1 is primarily too small.
  One of the peculiarities of our data is the observation that 
baseline PVR in patients who underwent BPH-related surgery 
had not changed at the time of surgery, despite a mean interval 
of 13.1 months after the initial visit. As presented in Table 2, 
changes in data occurred only in Qmax, which increased after 
medication therapy. The unchanged IPSS in these data indicates 
that the unsatisfactory improvement of symptoms was the main 
reason for this surgical conversion. All patients enrolled had 
visited the clinic for evaluation of LUTS symptoms; thus, al-
though Qmax increased after medication during the follow-up, 
nonresponders in terms of symptom score or PVR may be at 
risk of surgical intervention. However, due to the inherent limi-
tations of retrospectively collected data, direct conclusions on 
this issue cannot be extracted. Finding answers to the above 
questions will require further investigation via comparative 
analysis. 
  Although the predictability of PVR for BPH progression was 
observed in this series, the very low odds ratio reflects the com-
plexity of clinical interpretation of increased PVR. Actually, al-
though no significant increase in baseline PVR in the BPH prog-
ress group and no change in PVR from baseline at the time of 
surgery were observed, the outcome of our attempt to determine 
clinically helpful cutoffs from these data was not satisfactory. 
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with 72% sensitivity and 67% specificity, this is not a clinically 
acceptable level, considering the lack of reproducibility of these 
tests [24]. Furthermore, the discrepancy between the actual 
amount of urine and PVR measured by ultrasonography has 
been reported to increase in the low-volume range of PVR [25]. 
In addition, although statistical significance was observed when 
the traditionally considered PVR cutoffs of 50 mL and 100 mL 
were applied to identify patients with BPH clinical progression 
[3], it is noteworthy that most of the patients at each cutoff level 
were maintained with medication therapy without the occur-
rence of BPH-related clinical events. 
  We still recognize several limitations in this series. As previ-
ously mentioned, the retrospective study design not only limited 
the collection of variables but also hindered consistent enroll-
ment of patients. Decisions on BPH-related surgery were made 
on the basis of the preference of each physician and patient rath-
er than strict guidelines. Pressure-flow study, which can defi-
nitely discriminate patients with BOO, was not evaluated. As 
with other community-based studies, uroflowmetry and PVR 
measurement were conducted only one time per event. Chang-
es in PVR in patients without BPH-related clinical events dur-
ing follow-up were not evaluated serially. Because all patients 
enrolled had LUTS, this outcome of PVR cannot be generalized 
to patients without voiding symptoms. Our data did not suggest 
a reasonable cutoff value for PVR to discriminate patients. In 
addition, this was a single-center study based on patients who 
visited a third-degree medical center. 
  In conclusion, our data with a minimum of 3 years of follow-
up indicate that increased PVR at the baseline evaluation is a 
significant indicator of BPH-related clinical events along with 
increased IPSS or prostate volume in symptomatic members of 
the Korean population. In patients who required BPH-related 
surgery, although maximal flow rate improved after medical 
treatment, the symptom score and amount of PVR did not 
change during follow-up. However, our inability to provide a 
clinically acceptable cutoff implies the unreliability of PVR as a 
single dependent parameter indicating BOO. Further investiga-
tions with proper designs to compensate for these limitations 
are required the take advantage of the obvious usefulness of the 
noninvasive variable of PVR in patients with BPH. 
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